259 related articles for article (PubMed ID: 24778997)
41. Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.
DeZern AE; Brodsky RA
Hematol Oncol Clin North Am; 2015 Jun; 29(3):479-94. PubMed ID: 26043387
[TBL] [Abstract][Full Text] [Related]
42. Paroxysmal nocturnal hemoglobinuria.
Čermák J
Vnitr Lek; 2018; 64(5):508-513. PubMed ID: 30193519
[TBL] [Abstract][Full Text] [Related]
43. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.
Risitano AM; Notaro R; Pascariello C; Sica M; del Vecchio L; Horvath CJ; Fridkis-Hareli M; Selleri C; Lindorfer MA; Taylor RP; Luzzatto L; Holers VM
Blood; 2012 Jun; 119(26):6307-16. PubMed ID: 22577173
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
[TBL] [Abstract][Full Text] [Related]
45. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.
Risitano AM; Ricklin D; Huang Y; Reis ES; Chen H; Ricci P; Lin Z; Pascariello C; Raia M; Sica M; Del Vecchio L; Pane F; Lupu F; Notaro R; Resuello RR; DeAngelis RA; Lambris JD
Blood; 2014 Mar; 123(13):2094-101. PubMed ID: 24497537
[TBL] [Abstract][Full Text] [Related]
46. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
Hill A; Rother RP; Arnold L; Kelly R; Cullen MJ; Richards SJ; Hillmen P
Haematologica; 2010 Apr; 95(4):567-73. PubMed ID: 20145265
[TBL] [Abstract][Full Text] [Related]
47. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
Front Immunol; 2019; 10():1639. PubMed ID: 31379839
[No Abstract] [Full Text] [Related]
48. Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype.
Carlisi M; Mancuso S; Caimi G; Siragusa S
Clin Hemorheol Microcirc; 2021; 79(4):491-503. PubMed ID: 32116238
[TBL] [Abstract][Full Text] [Related]
49. [Novel therapeutics for paroxysmal nocturnal hemoglobinuria].
Nishimura JI
Rinsho Ketsueki; 2021; 62(5):463-471. PubMed ID: 34108330
[TBL] [Abstract][Full Text] [Related]
50. Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.
Risitano AM; Rotoli B
Biologics; 2008 Jun; 2(2):205-22. PubMed ID: 19707355
[TBL] [Abstract][Full Text] [Related]
51. [A reference guide for paroxysmal nocturnal hemoglobinuria: recent updates and points of medical treatment].
Gotoh A
Rinsho Ketsueki; 2020; 61(9):1080-1088. PubMed ID: 33162502
[TBL] [Abstract][Full Text] [Related]
52. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
53. Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria.
Risitano AM; Marotta S
Am J Hematol; 2018 Aug; 93(4):564-577. PubMed ID: 29314145
[TBL] [Abstract][Full Text] [Related]
54. [Current treatment of paroxysmal nocturnal hemoglobinuria and prospects for new therapeutic agents in the future].
Nishimura JI
Rinsho Ketsueki; 2021; 62(5):378-387. PubMed ID: 34108318
[TBL] [Abstract][Full Text] [Related]
55. Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.
Kelly RJ; Holt M; Vidler J; Arnold LM; Large J; Forrest B; Barnfield C; Pike A; Griffin M; Munir T; Muus P; Nagumantry SK; Varghese A; Davies JR; Trikha R; Kulasekararaj AG; Mitchell L; Gandhi S
Blood; 2024 Mar; 143(12):1157-1166. PubMed ID: 38142401
[TBL] [Abstract][Full Text] [Related]
56. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
[TBL] [Abstract][Full Text] [Related]
57. Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria.
Begum F; Khan N; Boisclair S; Malieckal DA; Chitty D
Am J Ther; 2023 May; 30(3):e209-e219. PubMed ID: 37104648
[TBL] [Abstract][Full Text] [Related]
58. A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going?
Griffin M; Kelly R; Pike A
Ther Adv Rare Dis; 2020; 1():2633004020959349. PubMed ID: 37180495
[TBL] [Abstract][Full Text] [Related]
59. Eculizumab for paroxysmal nocturnal haemoglobinuria.
Parker C
Lancet; 2009 Feb; 373(9665):759-67. PubMed ID: 19144399
[TBL] [Abstract][Full Text] [Related]
60. Paroxysmal nocturnal hemoglobinuria: Where are we going.
Kulasekararaj AG; Lazana I
Am J Hematol; 2023 May; 98 Suppl 4():S33-S43. PubMed ID: 36794458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
